Vertex Pharmaceuticals Incorporated
IT ˙ BIT ˙ US92532F1003
366,30 € ↓ -1,30 (-0,35%)
2026-06-03
AKTIENPREIS
SecurityIT:1VRTX / Vertex Pharmaceuticals Incorporated
InstitutionCreative Planning
Latest Disclosed Ownership109,524 shares
Latest Disclosed Value $ 48,906,949
Creative Planning ownership in 1VRTX / Vertex Pharmaceuticals Incorporated

On May 12, 2026 - Creative Planning filed a 13F-HR form disclosing ownership of 109,524 shares of Vertex Pharmaceuticals Incorporated (IT:1VRTX) valued at $41,575,310 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 100,513 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 8.97% during the quarter. The current value of the position is $40,118,641 USD.

Creative Planning has a history of taking positions in derivatives of the underlying security (1VRTX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

IT:1VRTX / Vertex Pharmaceuticals Incorporated Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 109,524 9,011 8.97 48,907 7.33 0.0332
2026-02-17 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 100,513 5,649 5.95 45,569 22.65 0.0326
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 94,864 7,690 8.82 37,153 -4.27 0.0284
2025-08-08 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 87,174 -1,666 -1.88 38,810 -9.90 0.0331
2025-05-15 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 88,840 9,370 11.79 43,071 34.59 0.0405
2025-02-14 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 79,470 -997 -1.24 32,002 -14.49 0.0311
2024-10-11 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 80,467 1,350 1.71 37,424 0.92 0.0371
2024-08-15 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 79,117 3,998 5.32 37,084 18.10 0.0396
2024-05-13 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 75,119 1,883 2.57 31,401 5.38 0.0348
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 73,236 -48,292 -39.74 29,799 -29.49 0.0553
2023-11-16 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 121,528 52,243 75.40 42,260 73.32 0.0564
2023-07-21 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 69,285 2,589 3.88 24,382 16.03 0.0325
2023-05-15 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 66,696 1,236 1.89 21,014 11.16 0.0303
2023-02-10 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 65,460 56,673 644.96 18,904 643.04 0.0284
2022-11-03 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,787 -4,318 -32.95 2,544 -31.11 0.0044
2022-08-15 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 13,105 7,280 124.98 3,693 142.96 0.0061
2022-05-16 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,825 -683 -10.49 1,520 6.37 0.0024
2022-02-11 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,508 -32,516 -83.32 1,429 -79.81 0.0023
2021-11-10 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 39,024 6,914 21.53 7,079 9.33 0.0126
2021-08-04 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 32,110 25,348 374.86 6,475 345.63 0.0115
2021-04-30 2021-03-31 13F CreativePlanning COM 92532F100 6,762 359 5.61 1,453 -3.97 0.0029
2021-01-29 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,403 -29 -0.45 1,513 -13.54 0.0033
2020-11-05 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,432 2,468 62.26 1,750 52.04 0.0046
2020-07-23 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,964 1,013 34.33 1,151 63.96 0.0033
2020-05-05 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,951 -564 -16.05 702 -8.71 0.0025
2020-01-30 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,515 134 3.96 769 34.21 0.0023
2019-11-01 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,381 -187 -5.24 573 -12.39 0.0019
2019-07-26 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,568 -423 -10.60 654 -10.90 0.0022
2019-04-24 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,991 -261 -6.14 734 4.11 0.0026
2019-02-12 2018-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 4,252 253 6.33 705 -8.56 0.0029
2019-02-01 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,252 253 705
2018-10-25 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,999 491 14.00 771 29.36 0.0029
2018-07-20 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,508 -132 -3.63 596 0.51 0.0023
2018-04-18 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,640 -723 -16.57 593 -9.33 0.0024
2018-01-17 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,363 513 13.32 654 11.79 0.0028
2017-10-17 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,850 134 3.61 585 22.13 0.0027
2017-07-12 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,716 917 32.76 479 56.54 0.0024
2017-04-07 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,799 -2,265 -44.73 306 -17.96 0.0017
2017-01-09 2016-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,064 -490 -8.82 373 -22.93 0.0023
2016-10-12 2016-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,554 305 5.81 484 7.32 0.0031
2016-07-12 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,249 102 1.98 451 10.27 0.0033
2016-04-08 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,147 -189 -3.54 409 -39.05 0.0032
2016-01-11 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,336 1,945 57.36 671 90.08 0.0055
2015-10-09 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,391 3,391 -36.45 353 -47.39 0.0031
2015-07-09 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -3,045 -100.00 0 -100.00
2015-04-13 2015-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,045 3,045 0.00 359 0.0034
2015-01-29 2014-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -1,263 -100.00 0 -100.00
2014-10-10 2014-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,263 -646 -33.84 142 -21.55 0.0016
2014-08-20 2014-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,909 547 40.16 181 88.54 0.0023
2014-04-11 2014-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,362 110 8.79 96 3.23 0.0014
2014-01-06 2013-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,252 8 0.64 93 -1.06 0.0016
2013-10-10 2013-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,244 374 42.99 94 34.29 0.0019
2013-07-09 2013-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 870 870 70 0.0016
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2021-08-04 2021-06-30 13F CreativePlanning COM Call 0 -100.00 0 n/a n/a n/a
2021-04-30 2021-03-31 13F CreativePlanning COM Call 100 0.00 0 n/a n/a n/a
2021-01-29 2020-12-31 13F VERTEX PHARMACEUTICALS COM Call 100 -90.00 0 -100.00 n/a n/a n/a
2020-11-05 2020-09-30 13F VERTEX PHARMACEUTICALS COM Call 1,000 900.00 128 n/a n/a n/a
2020-05-05 2020-03-31 13F VERTEX PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2020-01-30 2019-12-31 13F VERTEX PHARMACEUTICALS COM Call 800 63 n/a n/a n/a
2019-02-12 2018-12-31 13F/A VERTEX PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2018-10-25 2018-09-30 13F VERTEX PHARMACEUTICALS COM Call 500 50 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.